PMID- 28890509
OWN - NLM
STAT- MEDLINE
DCOM- 20180703
LR  - 20180703
IS  - 1884-2836 (Electronic)
IS  - 1344-6304 (Linking)
VI  - 70
IP  - 6
DP  - 2017 Nov 22
TI  - Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other 
      Quinolones.
PG  - 616-620
LID - 10.7883/yoken.JJID.2017.068 [doi]
AB  - The pharmacokinetic-pharmacodynamic (PK-PD) breakpoints (BPs) of garenoxacin 
      (GRNX) and other oral quinolones were calculated using Monte Carlo simulation 
      (MCS) based on the distribution of changes in their plasma concentrations. PK-PD 
      BPs of 400 mg once a day (QD) of GRNX for the free area under the curve/minimum 
      inhibitory concentration (fAUC/MIC) for 30 strains of Streptococcus pneumoniae 
      and 100 strains of gram-negative bacteria (G [－]) were 0.5 and 0.125 mug/mL, 
      respectively. PK-PD BPs of other quinolones for S. pneumoniae/G (－) were 1/0.25 
      mug/mL for levofloxacin (LVFX) 500 mg QD, 0.5/0.125 mug/mL for moxifloxacin (MFLX) 
      400 mg QD, 0.0625/0.0156 mug/mL for sitafloxacin (STFX) 50 mg twice a day (BID) 
      (100 mg QD), and 0.125/0.0313 mug/mL for STFX 100 mg BID. We also investigated the 
      hypothetical probability of target attainments (PTAs) of fAUC/MIC for 
      community-acquired pneumonia (CAP) using MCS, in consideration of the isolation 
      frequencies of the three main causative pathogens of CAP: S. pneumoniae, 
      Haemophilus influenzae, and Moraxella catarrhalis. For hypothetical CAP in 
      adults, PTA of fAUC/MIC was 100% with GRNX and MFLX, 96%-97% with STFX at 100 mg 
      BID, 45%-46% with LVFX, and 53%-58% with STFX at 100 mg QD and 50 mg BID. Based 
      on the PK-PD BP, GRNX showed higher fAUC/MIC than the other quinolones tested 
      against the three main pathogens of respiratory infections.
FAU - Yamagishi, Yuka
AU  - Yamagishi Y
AD  - Department of Clinical Infectious Diseases, Aichi Medical University.
FAU - Shibata, Tatsuya
AU  - Shibata T
AD  - Corporate Planning Department, Toyama Chemical Co., Ltd.
FAU - Nakagawa, Satoshi
AU  - Nakagawa S
AD  - Pharmaceutical & Healthcare Research Laboratories, FUJIFILM Corporation.
FAU - Nomura, Nobuhiko
AU  - Nomura N
AD  - Product Research Department, Toyama Chemical Co., Ltd.
FAU - Mitsuyama, Junichi
AU  - Mitsuyama J
AD  - Development Division, Toyama Chemical Co., Ltd.
FAU - Mikamo, Hiroshige
AU  - Mikamo H
AD  - Department of Clinical Infectious Diseases, Aichi Medical University.
LA  - eng
PT  - Journal Article
DEP - 20170911
PL  - Japan
TA  - Jpn J Infect Dis
JT  - Japanese journal of infectious diseases
JID - 100893704
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Quinolones)
RN  - V72H9867WB (garenoxacin)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Bacterial Agents/administration & dosage/*pharmacokinetics
MH  - Area Under Curve
MH  - Community-Acquired Infections/drug therapy/microbiology
MH  - Fluoroquinolones/administration & dosage/*pharmacokinetics
MH  - Humans
MH  - Microbial Sensitivity Tests
MH  - Monte Carlo Method
MH  - Pneumonia, Bacterial/drug therapy/microbiology
MH  - Quinolones/administration & dosage/*pharmacokinetics
MH  - Streptococcus pneumoniae/drug effects
OTO - NOTNLM
OT  - Community-acquired pneumonia
OT  - Garenoxacin
OT  - Monte Carlo simulation
OT  - Pharmacokinetic-pharmacodynamic breakpoint
EDAT- 2017/09/12 06:00
MHDA- 2018/07/04 06:00
CRDT- 2017/09/12 06:00
PHST- 2017/09/12 06:00 [pubmed]
PHST- 2018/07/04 06:00 [medline]
PHST- 2017/09/12 06:00 [entrez]
AID - 10.7883/yoken.JJID.2017.068 [doi]
PST - ppublish
SO  - Jpn J Infect Dis. 2017 Nov 22;70(6):616-620. doi: 10.7883/yoken.JJID.2017.068. 
      Epub 2017 Sep 11.